CNS-pen. GABAA-α5 neg. allo. mod. (NAM) Ph. II for Down syndrome (240 mg BID) from 56k cmpd competition binding HTS Sci. Rep., Apr. 8, 2021 Roche Innovation Center, Basel, CH